1. INTRODUCTION AND RATIONALE 
1.2 Pharmaceutical information on Xaliproden 
1.2.1 Chemistry 
1.2.2 Preclinical data 
1.2.3 Pharmacokinetic properties 
1.2.4 Preclinical safety data (toxicology) 
1.2.5 Clinical safety data 
2. STUDY OBJECTIVES 
2.1 Primary 
2.2 Secondary 
3. STUDY DESIGN 
3.1 Description of the protocol 
3.2 Interim analysis 
3.3 Study committees : Independent Data Monitoring Committee 
3.4 Duration of study participation 
4. SELECTION OF PATIENTS 
4.1 Number of patients planned : sample size 
4.2 Inclusion criteria 
4.3 Exclusion criteria 
5. TREATMENT 
5.1 Investigational Product 
5.2 Chemotherapy under study 
5.2.1 Oxaliplatin 
5.2.2 5 fluorouracil and leucovorin 
5.3 Treatment administration 
5.4 Guidelines for treatment modifications 
5.4.1 Chemotherapy treatment delay 
5.4.2 Dose reductions 
5.4.2.1 Dose reduction for Hematologic toxicity : 
5.4.2.2 Dose Reduction for Non Hematologic toxicities 
5.4.2.3 Peripheral neuropathy 
5.4.2.4 Laryngopharyngeal dysesthesias 
5.4.2.5 Oral cryotherapy 
5.4.2.6 Allergic Reactions 
5.4.2.7 Pulmonary fibrosis 
5.4.2.8 Other toxicities or miscellaneous events 
5.5 Description of blinding methods 
5.7 Packaging and labeling 
5.7.1 Xaliproden 
5.7.2 Oxaliplatin 
5.8 Storage conditions 
5.9 Responsibilities 
5.10 Retrieval of treatments and/or destruction 
5.11 Concomitant therapy 
5.11.1 Not permitted concomitant therapy 
5.11.2 Permitted concomitant therapy 
5.12 Study drug compliance 
6. ASSESSMENT OF INVESTIGATIONAL PRODUCT 
6.1 Efficacy 
6.1.2 Antitumoral efficacy 
6.1.3 Clinical assessment methods 
6.2 Safety 
7. PATIENT SAFETY 
7.1 Adverse Events monitoring 
7.2 Safety instructions specific to the study 
7.3 Laboratory tests monitoring 
8. HANDLING OF STUDY TREATMENT DISCONTINUATION 
8.1 List of withdrawal criteria 
8.2 Reasons for withdrawal 
8.3 Withdrawal follow up procedure 
8.4 Consequence 
9. STUDY PROCEDURES 
9.1 Visit schedule 
9.1.1 Baseline 
9.1.2 Evaluation during the treatment period 
9.1.3 Before each cycle (every 2 weeks) 
9.1.4 Every 4 cycles (8 weeks) / after 12 cycles 
9.1.5 End of study treatment Visit (30 day post chemotherapy) 
9.1.6 Post treatment Follow up 
9.2 Definition of source data 
9.3 Access to the randomization code during the study 
10. STATISTICAL CONSIDERATIONS 
10.1 Statistical and analytical plans 
10.2 Determination of sample size 
10.3 Interim Analysis 
10.4 Study patient description 
10.4.1 Disposition of patients 
10.4.2 Protocol deviations 
10.5 Data analysis considerations 
10.5.1 Dataset analyzed 
10.5.1.2 Populations to be analyzed 
10.5.2 General statistical approach 
10.5.3 General convention 
10.5.3.2 Other specific conventions 
10.6 Demographic and baseline characteristics 
10.6.2 Previous medications 
10.6.3 Baseline efficacy/activity data 
10.6.4 Baseline safety parameters 
10.7 Study drug and concomitant therapy 
10.7.1.2 Measurement of treatment compliance of xaliproden/placebo 
10.7.2 Concomitant medication/therapy 
10.8 Efficacy / activity analysis 
10.8.1 Primary efficacy variable(s) 
10.8.1.2 Primary analysis 
10.8.1.3 Other analyses for primary variable(s) 
10.8.2 Secondary / other efficacy variables 
10.9 Safety analysis 
10.9.1 Adverse Events 
10.9.1.1 Definitions 
10.9.1.2 Treatment emergent Adverse Events 
10.9.1.3 Deaths and Serious Adverse Events 
10.9.1.4 Adverse Events leading to treatment discontinuation 
10.9.2 Clinical laboratory evaluations 
10.9.3 Vital signs 
11. ETHICAL AND REGULATORY STANDARDS 
11.1 Ethical principles 
11.2 Laws and regulations 
11.3 Informed consent 
11.4 Institutional Review Board/Independent Ethics Committee (IRB/IEC/REB) 
12. STUDY MONITORING 
12.1 Responsibilities of the Investigator(s) 
12.2 Responsibilities of the Sponsor 
12.3 Source document requirements 
12.4 Use and completion of Case Report Forms (CRFs) and additional request 
13. ADMINISTRATIVE RULES 
13.1 Curriculum Vitae 
13.2 Record retention in study sites(s) 
14. CONFIDENTIALITY 
15. OWNERSHIP OF DATA AND USE OF THE STUDY RESULTS 
16. INSURANCE COMPENSATION 
17. SPONSOR AUDITS AND INSPECTIONS BY REGULATORY AGENCIES 
18. PREMATURE DISCONTINUATION OF THE STUDY OR PREMATURE CLOSE 
18.1 Decided by the Sponsor in the following cases: 
18.2 Decided by the Investigator 
19. CLINICAL STUDY REPORT 
20. PUBLICATIONS 
21. PROTOCOL AMENDMENTS 
22. BIBLIOGRAPHIC REFERENCES 